Clinical Trial Accrual: Obstacles and Opportunities

Clinical Trial Accrual: Obstacles and Opportunities

Less than 2% of patients diagnosed with cancer participate in a clinical trial in the United States (1). Gynecologic oncology patients do not appear to participate in trials with any more frequently than other cancer types. While gains in progression free survival have continued to improve overall life span for women with advanced gynecologic cancers, more cures have not been realized. Clinical...

Health Tourism: Opportunities, Constraints, Obstacles and Solutions

Obstacles and Opportunities

Management theory teaches that successful innovation requires concomitant changes among the system ’ s components to achieve congruence or fi t . 1 Similar thinking has been applied to changing the U.S. health care system. 2 In recent years, there has been growing recognition that payment reform of the U.S. health care system must be accompanied by corresponding reforms in the delivery system. ...

Neuroepigenomics: resources, obstacles, and opportunities

Long-lived post-mitotic cells, such as the majority of human neurons, must respond effectively to ongoing changes in neuronal stimulation or microenvironmental cues through transcriptional and epigenomic regulation of gene expression. The role of epigenomic regulation in neuronal function is of fundamental interest to the neuroscience community, as these types of studies have transformed our un...

Clinical trial development as a predictor of accrual performance--letter.

In the November 15, 2010 edition of Clinical Cancer Research, Cheng and colleagues describe an important finding, namely, the association between trial development time and accrual success (1). Their article also reports accrual success rates for NCI Cancer Therapy Evaluation Program (CTEP)-sponsored trials. This publication formally publishes the finding that 40% of cancer clinical trials of a...